86 related articles for article (PubMed ID: 11673740)
21. Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-alpha.
Boulestin A; Sandres-Sauné K; Payen JL; Alric L; Dubois M; Pasquier C; Vinel JP; Pascal JP; Puel J; Izopet J
J Med Virol; 2002 Oct; 68(2):221-8. PubMed ID: 12210411
[TBL] [Abstract][Full Text] [Related]
22. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
23. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.
Fernández I; Castellano G; de Salamanca RE; Colina F; Gómez de la Cámara A; Morán MJ; Muñoz R; Solís-Herruzo JA
Scand J Gastroenterol; 2003 Mar; 38(3):314-9. PubMed ID: 12737448
[TBL] [Abstract][Full Text] [Related]
24. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
25. Serum immunoglobulins in patients with chronic hepatitis C: a surrogate marker of disease severity and treatment outcome.
Maruyama S; Hirayama C; Horie Y; Yorozu K; Maeda K; Inoue M; Fujii Y; Umeki K; Koda M
Hepatogastroenterology; 2007 Mar; 54(74):493-8. PubMed ID: 17523306
[TBL] [Abstract][Full Text] [Related]
26. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors.
Yu ML; Dai CY; Chen SC; Lee LP; Huang JF; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Chang WY
Antiviral Res; 2004 Jul; 63(1):25-32. PubMed ID: 15196817
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between diversity of hepatitis C virus quasispecies and viremia, activity of liver disease and response to interferon therapy].
Tang X; Qian K; Yuan X; Johnson YN
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):128-31. PubMed ID: 12196822
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
Beard MR
Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
[No Abstract] [Full Text] [Related]
29. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
[TBL] [Abstract][Full Text] [Related]
30. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
31. Effect of interferon therapy on fatty acid saturation index in hepatitis C virus infection.
Abdel Aziz MT; Abdel-Ghaffar Y; Fouad HH; Abdel Aziz DM; el-Magd AA
East Mediterr Health J; 2001; 7(4-5):779-86. PubMed ID: 15332779
[TBL] [Abstract][Full Text] [Related]
32. [Chronic hepatitis. 3. An actual case].
Moradpour D; Blum HE
Dtsch Med Wochenschr; 2001 Jul; 126(27):789; quiz 790-2. PubMed ID: 11510460
[No Abstract] [Full Text] [Related]
33. New infection with heterotypic hepatitis C virus in a patient with long-term hepatitis C virus eradication.
De Mitri MS; Cassini R; Morsica G; Bagaglio S; Zoli M; Bernardi M
Dig Liver Dis; 2001 Oct; 33(7):591-4. PubMed ID: 11816550
[TBL] [Abstract][Full Text] [Related]
34. Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy?
Loguercio C; Caporaso N; Tuccillo C; Morisco F; Del Vecchio Blanco G; Del Vecchio Blanco C
J Hepatol; 1998 Mar; 28(3):390-5. PubMed ID: 9551675
[TBL] [Abstract][Full Text] [Related]
35. [Chronic hepatitis. 5: Therapy of chronic viral hepatitis, especially hepatitis C].
Schlaak JF; Gerken G
Fortschr Med; 1997 Sep; 115(25):48-50. PubMed ID: 9378444
[No Abstract] [Full Text] [Related]
36. Eradication of hepatitis C virus RNA after alpha-interferon therapy.
Romeo R; Pol S; Berthelot P; Brechot C
Ann Intern Med; 1994 Aug; 121(4):276-7. PubMed ID: 8037409
[No Abstract] [Full Text] [Related]
37. [The dynamic changes of hepatitis C virus quasispecies during natural infections].
Fan WM; Zhu WF; Wei L; Yin LM
Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):839-41. PubMed ID: 17125615
[No Abstract] [Full Text] [Related]
38. A patient with hepatitis C virus infection and inflammatory polyarthritis.
Thomas NS; Kerr G; Benator D; Lichy JH
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1885-91. PubMed ID: 24591412
[No Abstract] [Full Text] [Related]
39. Chronic hepatitis C virus infection with repeatedly normal aminotransferase levels: disease or not disease?
Pawlotsky JM
Am J Gastroenterol; 1997 Oct; 92(10):1775-7. PubMed ID: 9382033
[No Abstract] [Full Text] [Related]
40. Chronic hepatitis C: grading, staging, and searching for reliable predictors of outcome.
Koukoulis GK
Hum Pathol; 2001 Sep; 32(9):899-903. PubMed ID: 11567217
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
